US Stock MarketDetailed Quotes
CERE Cerevel Therapeutics Holdings
- 42.470
- +0.400+0.95%
Close Apr 26 16:00 ET
- 42.800
- +0.330+0.78%
Post 19:26 ET
7.71BMarket Cap-15906P/E (TTM)
42.491High41.930Low680.91KVolume42.020Open42.070Pre Close28.85MTurnover0.88%Turnover RatioLossP/E (Static)181.58MShares43.59052wk High11.44P/B3.28BFloat Cap19.59052wk Low--Dividend TTM77.23MShs Float46.161Historical High--Div YieldTTM1.33%Amplitude9.000Historical Low42.377Avg Price1Lot Size
Cerevel Therapeutics Holdings Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -16.75%-342.3M | -11.37%-97.42M | 9.67%-72.63M | -34.12%-77.33M | -40.32%-94.92M | -64.21%-293.19M | -65.85%-87.48M | -83.67%-80.41M | -26.42%-57.66M | -85.75%-67.65M |
| Net income from continuing operations | -23.14%-432.84M | -42.94%-132.66M | 3.58%-96.36M | -10.02%-99.54M | -52.70%-104.29M | -56.00%-351.51M | -57.16%-92.81M | -61.04%-99.94M | -69.93%-90.47M | -33.96%-68.29M |
| Depreciation and amortization | 14.77%5.63M | 16.14%1.5M | 14.36%1.45M | 10.63%1.35M | 18.16%1.32M | 79.53%4.9M | 19.14%1.3M | 29.29%1.27M | 103.49%1.22M | 1,674.60%1.12M |
| Other non cash items | 377.73%19.09M | 167.68%5.52M | -200.87%-7.64M | 569.04%9.94M | 369.97%11.27M | -1,122.92%-6.87M | -47.09%-8.15M | 34.70%7.57M | -373.07%-2.12M | -2,169.57%-4.18M |
| Change In working capital | -42.58%16.11M | 14.64%8.52M | 490.70%17.33M | -96.20%879K | -96.38%-10.62M | 80.58%28.06M | 74.52%7.43M | -23.51%2.93M | 3,512.70%23.1M | -166.56%-5.41M |
| -Change in prepaid assets | -74.98%-1.99M | -5.25%-4.93M | 1,997.21%4.51M | -193.68%-1.42M | -108.12%-147K | 78.39%-1.14M | 32.52%-4.69M | 135.95%215K | -17.57%1.52M | 325.12%1.81M |
| -Change in payables and accrued expense | -35.26%19.45M | 8.78%13.6M | 345.28%13.07M | -87.06%2.81M | -41.04%-10.03M | 88.36%30.04M | 10.94%12.5M | 56.95%2.94M | 1,027.72%21.72M | -238.07%-7.11M |
| -Change in other current assets | -59.69%-1.34M | 61.30%-149K | -14.35%-247K | -278.36%-507K | -315.09%-440K | -14.73%-841K | -466.18%-385K | -334.78%-216K | 82.04%-134K | -863.64%-106K |
| -Change in other current liabilities | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -16.75%-342.3M | -11.37%-97.42M | 9.67%-72.63M | -34.12%-77.33M | -40.32%-94.92M | -64.21%-293.19M | -65.85%-87.48M | -83.67%-80.41M | -26.42%-57.66M | -85.75%-67.65M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 118.96%73.72M | -461.90%-150.21M | 113.25%51.39M | -3.95%61.75M | 387.43%110.78M | 10.75%-388.83M | 93.73%-26.73M | -32,547.64%-387.85M | 1,894.42%64.29M | -727.08%-38.54M |
| Net PPE purchase and sale | 3.69%-3.81M | -98.68%-902K | -200.00%-513K | -81.71%-2.06M | 84.71%-336K | 62.35%-3.95M | 57.65%-454K | 85.61%-171K | 68.41%-1.13M | 52.85%-2.2M |
| Net investment purchase and sale | 120.14%77.53M | -468.18%-149.31M | 113.39%51.91M | -2.47%63.81M | 405.73%111.12M | 9.47%-384.88M | 93.82%-26.28M | ---387.68M | --65.43M | ---36.35M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 118.96%73.72M | -461.90%-150.21M | 113.25%51.39M | -3.95%61.75M | 387.43%110.78M | 10.75%-388.83M | 93.73%-26.73M | -32,547.64%-387.85M | 1,894.42%64.29M | -727.08%-38.54M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -11.97%548.62M | 23,756.03%508.37M | -99.79%1.2M | -5.53%37.61M | -44.87%1.44M | 47.12%623.19M | -7.99%2.13M | 49.30%578.64M | 20.79%39.82M | 250.81%2.6M |
| Net issuance payments of debt | --0 | --0 | ---- | ---- | ---- | --334.77M | ---63K | ---- | ---- | ---- |
| Net common stock issuance | 109.41%498.94M | 875,440.35%498.94M | ---- | ---- | ---- | -27.41%238.26M | ---57K | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | 42.21%18.56M | 293.16%9.43M | -78.21%1.2M | 174.78%6.36M | -44.85%1.57M | -79.75%13.05M | -10.22%2.4M | -90.74%5.48M | 26.63%2.32M | 284.64%2.85M |
| Net other financing activities | -16.15%31.11M | --0 | --0 | -16.67%31.25M | 44.62%-139K | 20.09%37.1M | 58.59%-147K | --0 | --37.5M | ---251K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -11.97%548.62M | 23,756.03%508.37M | -99.79%1.2M | -5.53%37.61M | -44.87%1.44M | 47.12%623.19M | -7.99%2.13M | 49.30%578.64M | 20.79%39.82M | 250.81%2.6M |
| Net cash flow | ||||||||||
| Beginning cash position | -29.83%138.39M | -37.05%157.68M | 26.87%177.72M | 66.27%155.68M | -29.83%138.39M | -49.15%197.22M | -62.83%250.47M | -57.71%140.09M | -73.05%93.63M | -49.15%197.22M |
| Current changes in cash | 576.01%280.04M | 332.64%260.74M | -118.16%-20.04M | -52.56%22.04M | 116.70%17.3M | 69.14%-58.83M | 76.49%-112.08M | -67.78%110.38M | 386.28%46.45M | -156.81%-103.59M |
| End cash Position | 202.36%418.43M | 202.36%418.43M | -37.05%157.68M | 26.87%177.72M | 66.27%155.68M | -29.83%138.39M | -29.83%138.39M | -62.83%250.47M | -57.71%140.09M | -73.05%93.63M |
| Free cash flow | -16.48%-346.11M | -11.82%-98.32M | 9.22%-73.14M | -35.03%-79.38M | -36.39%-95.26M | -57.18%-297.14M | -63.39%-87.93M | -79.20%-80.58M | -19.51%-58.79M | -70.03%-69.85M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg